

## References

### I-202

1. Dai J, Almazan TH, Hong EK, Khodadoust MS, Arai S, Weng W, et al. Potential association of anti-CCR4 antibody mogamulizumab and graft-vs-host disease in patients with mycosis fungoides and sezary syndrome. *JAMA Dermatology*. 2018;154(6):728-730.
2. Micromedex DrugDex Compendium®. 2024. Mogamulizumab-kpkc.
3. Clinical Pharmacology™ Compendium. 2024. Tampa FL: Gold Standard, Inc. Mogamulizumab-kpkc.
4. Poteligeo® (Mogamulizumab-kpkc) injection, for intravenous use [package insert]. Bedminster, NJ. Kyowa Kirin, Inc. Revised 03/2022.
5. National Comprehensive Cancer Network (NCCN). Mogamulizumab-kpkc. NCCN Drugs and Biologics Compendium®. 2024.
6. Scarisbrick J, Geskin LJ, Bagot M, et al. Efficacy of mogamulizumab in previously treated patients with less advanced mycosis fungoides: results from the mavoric study. *Hematological Oncology*. 2019;37:6667.
7. Phillips AA, Fields PA, Hermine O, et al. Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. *Haematologica*. 2019;104(5):993-1003.
8. Mogamulizumab-kpkc. In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 9, 2020.
9. Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. *Lancet Oncol*. 2018;19(9):1192-1204.